Tyme 2 1 4 0

Return to site

Tyme 2 1 4 0

Time 2140600
Tyme 2 1 4 0 5
Tyme 2 In 1
This article reveals the differences between thyme and oregano:
Thyme Find the latest Tyme Technologies, Inc. (TYME) stock quote, history, news and other vital information to help you with your stock trading and investing. 2.0 star rating Score 2. 1.0 star rating Score 1. All All reviews. With Images & Videos Images only. Show 1805 Reviews. All; 5.0 star rating. You will read reviews about it being hard to use and it will make you scared of the tyme. Seriously, get on YouTube and watch and learn BEFORE going at it.
Burger Tyme is home of Louisiana's original Cajun Blaze. We supply our famous, authentic Cajun Seasoning to your table, just as it was originally intended. Drizzle the vegetables with the oil, season them with the pepper and thyme, and toss gently to coat. Roast the vegetables uncovered for 20-35 minutes, stirring occasionally, until they turn golden brown. If you like, squeeze a little lemon juice over when serving. The smaller you chop the cauliflower, the less time it takes to bake. Thyme White statistics and form. View results and future entries as well as statistics by course, race type and prize money.
It is the leaf in the mint family – Thymus vulgaris. It has been used in ancient times in countries such as Egypt and Greece for various purposes, like – seizures and embalming.
Thyme can be used either dried or fresh and possesses a strong, characteristic odor that bears a slight similarity with mint.
OreganoIt is an aromatic perennial herb that can grow to approximately 2 feet in height. Oregano is native to the Mediterranean region. Currently, Turkey is one of the largest exporters.
In Italy and Greece, it is commonly used at weddings since it is considered to be a symbol of joy.
Time 2140600Oregano is also seen as a staple herb in a variety of comfort foods, vegetable dishes, soups, and scrambled eggs.
1 tbsp (4g) of dried thyme contains:
11 calories;
1.4g Fiber – 6% daily value;
0.4g Protein – 1% DV;
240 IU Vitamin A – 4% DV;
2mg Vitamin C – 2% DV;
0.6 mg Vitamin E – 4% DV;
22mcg Vitamin K – 30% DV;
0.2mg Niacin – 1% DV;
0.1mg Vitamin B6 – 1% DV;
9mcg Folate – 2% DV;
1.2mg Choline;
55mg Calcium – 5% DV;
1.6mg Iron – 8% DV;
9mg Magnesium – 2% DV;
7mg Phosphorus – 1% DV;
60mg Potassium – 2% DV;
0.2mg Zinc – 1% DV;
0.1mg Copper – 1% DV;
0.1mcg Selenium – 1% DV.
The most active ingredient found in thyme is thymol, which has a wide range of effects on the body, including its capacity to prevent viral and fungal infections, hence reducing strain on the immune system. Collections 4 0 1 – organize your desktop icons shortcut.
Moreover, thymol is 25 times more efficient than phenol, a powerful antiseptic used in medicine. Thymol may also help to increase omega-3 fatty acids, according to a 2005 study published in 'Nature.'
File multi tool 6 2007. 1 tbsp (4g) of dried oregano contains:
Tyme 2 1 4 0 512 calories;
1.6g Fiber – 6% daily value;
0.4g Protein – 1% DV;
162 IU Vitamin A – 3% DV;
2mg Vitamin C – 4% DV;
0.3 mg Vitamin E – 2% DV;
73mcg Vitamin K – 91% DV;
0.0mg Thiamin – 1% DV;
0.0mg Riboflavin –1% DV;
0.2mg Niacin – 1% DV;
0.0mg Vitamin B6 – 1% DV;
12mcg Folate – 3% DV;
1.9mg Choline;
80mg Calcium – 8% DV;
5.3mg Iron – 29% DV;
9mg Magnesium – 2% DV;
8mg Phosphorus – 1% DV;
35mg Potassium – 1% DV;
0.2mg Zinc – 1% DV;
0.3mg Copper – 17% DV.
Note – the chemicals which give the herb its flavor are carvacrol, ocimene, thymol, pinene, limonene, and caryophyllene.
ThymePowerful Antibacterial Thyme is a good source of carvacrol and thymol that have powerful antifungal, antibacterial, and antiviral properties. Due to this fact, thyme is very effective in fighting against the numerous disease-causing microbes.
Note – due to its antibacterial and antifungal attributes, thymol is found in the formula of a variety of antiseptic mouthwashes which are sold in pharmacies to treat canker sores, infections of the throat and gums (gingivitis), inflammation of the mouth, and halitosis (bad breath).
Antioxidant PropertiesThyme is an excellent source of antioxidants like apigenin, saponins, luteolin, and tannins. These compounds help neutralize free radicals (a group of atoms that have an unpaired electron) before they can cause oxidative stress and harm.
Vitamin KVitamin K plays an important role in helping the human body to produce blood-clotting proteins.
Also, this vitamin is essential for the maintenance of the arterial wall and the regulation of cell growth.
Signs and symptoms of a deficiency in vitamin K may include:
heavy menstrual bleeding;
easy bruising;
excessive bleeding, from a wound, injection, cut, or puncture.
1 tbsp (4g) of dried thyme contains 22mcg of vitamin K that is about 30 percent of the daily recommended intake.
OreganoCancer PreventionA 2009 study done at the Department of Experimental Medicine and Biochemical Sciences, Rome, Italy established that treating human colon cancer cells with an extract from oregano helped kill the cancer cells.
Another 2014 study conducted at the Department of Physiology and Pharmacology, Federal University of Pelotas, Brazil, and issued in the Journal of Medicinal Food established that a compound found in oregano, called – 4-terpineol, was effective at inhibiting the spread of cancer cells.

HeartburnHeartburn is a sour or bitter taste in the mouth and throat along with a burning feeling in the lower chest. The condition occurs when the valve between the esophagus and the stomach are unable to prevent the acid in the stomach from passing back into the esophagus.
Several of the active compounds found in oregano can help digestion by relaxing the muscles of the gastrointestinal tract. Pdf library manager mac. This reduces the incidence of heartburn.
Dietary FiberTyme 2 In 1Fiber is a carbohydrate that isn't broken down and absorbed by the body and is found in plant foods, like – fruits, beans, nuts, grains, seeds, herbs, and vegetables.
Here are some benefits of dietary fiber:
it sweeps the intestinal tract for plaques which might be disease precursors;
it helps emulsify fat and inhibit its absorption in the body;
feeds the beneficial bacteria in the colon;
loosens up the stool for a better bowel movement;
gives you a sense of fullness in the stomach, promoting weight loss and weight management.
1 tbsp (4g) of dried oregano contains 1.6 grams of dietary fiber that is about 6 percent of the daily recommended intake.
CalciumCalcium is an essential mineral which helps your body with: Clean text menu 2 20 download free.
keeping a normal heartbeat;
building strong bones and teeth (over 99 percent of the calcium in your body is stored in your bones and teeth);
releasing hormones and other chemicals;
relaxing and squeezing muscles;
sending and receiving nerve signals;
clotting blood.
1 tbsp (4g) of dried oregano contains 80 mg of calcium that is about 8% of the daily recommended intake.
Thyme vs Oregano – TasteThyme has a gentle flavor and a taste that is a bit earthy with minty and lemony tones.
The taste of oregano has a little sweet and bitter flavor and it gives you a peppery flavor. Dried oregano has a stronger flavor than the fresh one. The Mexican type has a distinctively different flavor that is less minty and less bitter than the other types.
Oral SM-88 represents a new approach designed to selectively disrupt protein synthesis in cancers with demonstrated responses in 15 different cancer types across four separate studies
Data presented at ESMO GI 2019 from TYME-88-PANC Phase II study demonstrated encouraging overall survival trends in patients with advanced pancreatic cancer
Targeted mechanism of action has resulted in fewer than 2% of patients experiencing serious adverse events related to SM-88 in all clinical trials
Enrollment is expected to begin in fourth quarter of 2019 at leading pancreatic cancer research centers across the United States 
NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the start of the pivotal stage of the TYME-88-Panc trial to evaluate the clinical benefits of its lead CMBT candidate, oral SM-88 (racemetyrosine), for third-line treatment of patients with metastatic pancreatic cancer. CMBTs are proprietary investigational compounds that are believed to disrupt cancer cells' protein synthesis, leading to a breakdown of the cancer's key defenses and cell death. In clinical trials, SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, prostate, sarcoma, breast, lung, and lymphoma cancers with minimal serious grade 3 or higher adverse events. 
'We believe that targeting cancer's metabolism by disrupting protein synthesis has advantages over existing treatment approaches for both efficacy and safety,' said Giuseppe Del Priore, M.D., Chief Medical Officer at TYME. 'In clinical studies to date, SM-88 had encouraging efficacy results and appears to be well-tolerated. The pancreatic phase II data demonstrated that new efficacy indicators, including achieving at least stable disease and decreasing circulating tumor cells following treatment with SM-88 correlate with greater overall survival in metastatic pancreatic cancer patients.'
Based on the encouraging results demonstrated in the Phase II portion of the TYME-88-Panc study of SM-88, TYME has designed the pivotal stage of the TYME-88-Panc study as a multi-center randomized (1:1), controlled pivotal trial that will evaluate the efficacy and safety of SM-88 used with MPS (methoxsalen, phenytoin, sirolimus) in patients with metastatic adenocarcinoma of the pancreas whose disease has progressed or recurred and have received two lines of prior systemic therapy. Approximately 250 patients will be randomized to receive a 920 mg dose of SM-88 with MPS daily (Arm A n=125) or one of three pre-defined single agent therapies (Arm B n=125). Patients will be treated until there is unacceptable toxicity or disease progression. The primary endpoint is overall survival (OS). Photoscape x pro 2 6. Key secondary endpoints include progression free survival (PFS), clinical benefit response rate (CBR), defined as patients achieving stable disease or better, circulating tumor cells (CTCs) and quality of life (QOL). The study will include leading pancreatic cancer research sites across the United States. Click here to learn more.
Recent results, based on data as of April 25, 2019, from the Phase II portion of the TYME-88-Panc study, were presented at the European Society of Medical Oncology 21st World Congress on Gastrointestinal Cancer in Barcelona, Spain on Wednesday, July 4, 2019 (link to poster). The study demonstrated a median overall survival in evaluable patients (38 of 49) of 6.4 months. These survival results compare very favorably to the analysis of 19 prospective pancreatic cancer trials where the median reported survival after progressing on second-line therapy was 2.0 – 2.5 months1 based on reported historical trials. In the Phase II portion of the TYME-88-Panc study, a RECIST CBR of stable disease or better was achieved by 44% of patients (11 of 25) with available imaging. Patients achieving stable disease or better demonstrated a statistically significant (p=0.02) improvement in survival with a 92% reduction in risk of death (hazard ratio=0.08). The CBR was durable with majority of patients remaining in stable disease or better for more than 7 months after receiving treatment with SM-88. The study showed a median reduction of 63% in CTC burden in evaluable patients. Patients (10 of 24) with available results reaching an 80% reduction or greater in CTCs demonstrated a 60% decrease in risk of death (hazard ratio=0.40).
Http freedownloadwinrar net. The Phase II portion of the TYME-88 Panc study reported that SM-88 was well tolerated with only 4.0% of patients (2 of 49) who experienced serious adverse events (SAEs) deemed at least possibly related to SM-88 (abdominal pain, arthralgia, and hypotension). One patient with reported SAEs continued on treatment.
Patients and physicians can access www.TYMETRIALS.com for more information about ongoing SM-88 clinical trials. SM-88 is not approved for the treatment of patients with any disease condition. 
About Advanced Pancreatic Cancer
Advanced pancreatic cancer is a difficult-to-treat cancer with the lowest survival rates among all cancer types. Across all patients with pancreatic cancer, relative 5-year survival is 8% and is less than 3% for those with advanced disease.2 The median survival for patients in end-stage of the disease is approximately 3 months. There are two main types of pancreatic cancer - adenocarcinomas, which accounts for approximately 90% of all pancreatic cancer, and neuroendocrine tumors. Pancreatic cancer is relatively uncommon with new cases accounting for only 2.1% of all newly diagnosed cancers. However, pancreatic cancer is the fourth most common cause of cancer death for men and women in the United States. 
About SM-88
SM-88 is an oral investigational modified proprietary tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells' key defenses and leading to cell death through oxidative stress and exposure to the body's natural immune system. Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious grade 3 or higher adverse events.
About Tyme Technologies
Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cancer cell death through oxidative stress and exposure to the body's natural immune system. For more information, visit www.tymeinc.com. Follow us on social media: @tyme_Inc, LinkedIn, Instagram, Facebook and YouTube.

HeartburnHeartburn is a sour or bitter taste in the mouth and throat along with a burning feeling in the lower chest. The condition occurs when the valve between the esophagus and the stomach are unable to prevent the acid in the stomach from passing back into the esophagus.
Several of the active compounds found in oregano can help digestion by relaxing the muscles of the gastrointestinal tract. Pdf library manager mac. This reduces the incidence of heartburn.
Dietary FiberTyme 2 In 1Fiber is a carbohydrate that isn't broken down and absorbed by the body and is found in plant foods, like – fruits, beans, nuts, grains, seeds, herbs, and vegetables.
Here are some benefits of dietary fiber:
it sweeps the intestinal tract for plaques which might be disease precursors;
it helps emulsify fat and inhibit its absorption in the body;
feeds the beneficial bacteria in the colon;
loosens up the stool for a better bowel movement;
gives you a sense of fullness in the stomach, promoting weight loss and weight management.
1 tbsp (4g) of dried oregano contains 1.6 grams of dietary fiber that is about 6 percent of the daily recommended intake.
CalciumCalcium is an essential mineral which helps your body with: Clean text menu 2 20 download free.
keeping a normal heartbeat;
building strong bones and teeth (over 99 percent of the calcium in your body is stored in your bones and teeth);
releasing hormones and other chemicals;
relaxing and squeezing muscles;
sending and receiving nerve signals;
clotting blood.
1 tbsp (4g) of dried oregano contains 80 mg of calcium that is about 8% of the daily recommended intake.
Thyme vs Oregano – TasteThyme has a gentle flavor and a taste that is a bit earthy with minty and lemony tones.
The taste of oregano has a little sweet and bitter flavor and it gives you a peppery flavor. Dried oregano has a stronger flavor than the fresh one. The Mexican type has a distinctively different flavor that is less minty and less bitter than the other types.
Oral SM-88 represents a new approach designed to selectively disrupt protein synthesis in cancers with demonstrated responses in 15 different cancer types across four separate studies
Data presented at ESMO GI 2019 from TYME-88-PANC Phase II study demonstrated encouraging overall survival trends in patients with advanced pancreatic cancer
Targeted mechanism of action has resulted in fewer than 2% of patients experiencing serious adverse events related to SM-88 in all clinical trials
Enrollment is expected to begin in fourth quarter of 2019 at leading pancreatic cancer research centers across the United States 
NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the start of the pivotal stage of the TYME-88-Panc trial to evaluate the clinical benefits of its lead CMBT candidate, oral SM-88 (racemetyrosine), for third-line treatment of patients with metastatic pancreatic cancer. CMBTs are proprietary investigational compounds that are believed to disrupt cancer cells' protein synthesis, leading to a breakdown of the cancer's key defenses and cell death. In clinical trials, SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, prostate, sarcoma, breast, lung, and lymphoma cancers with minimal serious grade 3 or higher adverse events. 
'We believe that targeting cancer's metabolism by disrupting protein synthesis has advantages over existing treatment approaches for both efficacy and safety,' said Giuseppe Del Priore, M.D., Chief Medical Officer at TYME. 'In clinical studies to date, SM-88 had encouraging efficacy results and appears to be well-tolerated. The pancreatic phase II data demonstrated that new efficacy indicators, including achieving at least stable disease and decreasing circulating tumor cells following treatment with SM-88 correlate with greater overall survival in metastatic pancreatic cancer patients.'
Based on the encouraging results demonstrated in the Phase II portion of the TYME-88-Panc study of SM-88, TYME has designed the pivotal stage of the TYME-88-Panc study as a multi-center randomized (1:1), controlled pivotal trial that will evaluate the efficacy and safety of SM-88 used with MPS (methoxsalen, phenytoin, sirolimus) in patients with metastatic adenocarcinoma of the pancreas whose disease has progressed or recurred and have received two lines of prior systemic therapy. Approximately 250 patients will be randomized to receive a 920 mg dose of SM-88 with MPS daily (Arm A n=125) or one of three pre-defined single agent therapies (Arm B n=125). Patients will be treated until there is unacceptable toxicity or disease progression. The primary endpoint is overall survival (OS). Photoscape x pro 2 6. Key secondary endpoints include progression free survival (PFS), clinical benefit response rate (CBR), defined as patients achieving stable disease or better, circulating tumor cells (CTCs) and quality of life (QOL). The study will include leading pancreatic cancer research sites across the United States. Click here to learn more.
Recent results, based on data as of April 25, 2019, from the Phase II portion of the TYME-88-Panc study, were presented at the European Society of Medical Oncology 21st World Congress on Gastrointestinal Cancer in Barcelona, Spain on Wednesday, July 4, 2019 (link to poster). The study demonstrated a median overall survival in evaluable patients (38 of 49) of 6.4 months. These survival results compare very favorably to the analysis of 19 prospective pancreatic cancer trials where the median reported survival after progressing on second-line therapy was 2.0 – 2.5 months1 based on reported historical trials. In the Phase II portion of the TYME-88-Panc study, a RECIST CBR of stable disease or better was achieved by 44% of patients (11 of 25) with available imaging. Patients achieving stable disease or better demonstrated a statistically significant (p=0.02) improvement in survival with a 92% reduction in risk of death (hazard ratio=0.08). The CBR was durable with majority of patients remaining in stable disease or better for more than 7 months after receiving treatment with SM-88. The study showed a median reduction of 63% in CTC burden in evaluable patients. Patients (10 of 24) with available results reaching an 80% reduction or greater in CTCs demonstrated a 60% decrease in risk of death (hazard ratio=0.40).
Http freedownloadwinrar net. The Phase II portion of the TYME-88 Panc study reported that SM-88 was well tolerated with only 4.0% of patients (2 of 49) who experienced serious adverse events (SAEs) deemed at least possibly related to SM-88 (abdominal pain, arthralgia, and hypotension). One patient with reported SAEs continued on treatment.
Patients and physicians can access www.TYMETRIALS.com for more information about ongoing SM-88 clinical trials. SM-88 is not approved for the treatment of patients with any disease condition. 
About Advanced Pancreatic Cancer
Advanced pancreatic cancer is a difficult-to-treat cancer with the lowest survival rates among all cancer types. Across all patients with pancreatic cancer, relative 5-year survival is 8% and is less than 3% for those with advanced disease.2 The median survival for patients in end-stage of the disease is approximately 3 months. There are two main types of pancreatic cancer - adenocarcinomas, which accounts for approximately 90% of all pancreatic cancer, and neuroendocrine tumors. Pancreatic cancer is relatively uncommon with new cases accounting for only 2.1% of all newly diagnosed cancers. However, pancreatic cancer is the fourth most common cause of cancer death for men and women in the United States. 
About SM-88
SM-88 is an oral investigational modified proprietary tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells' key defenses and leading to cell death through oxidative stress and exposure to the body's natural immune system. Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious grade 3 or higher adverse events.
About Tyme Technologies
Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cancer cell death through oxidative stress and exposure to the body's natural immune system. For more information, visit www.tymeinc.com. Follow us on social media: @tyme_Inc, LinkedIn, Instagram, Facebook and YouTube.
Forward-Looking Statements/Disclosure Notice
In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding our drug candidate SM-88 and its clinical potential and non-toxic safety profiles, our drug development plans and strategies, ongoing and planned clinical trials, preliminary data results and the therapeutic design and mechanisms of our drug candidates; and readers can identify forward-looking statements by sentences or passages involving the use of terms such 'believes,' 'expects,' 'hopes,' 'may,' 'will,' 'plan,' 'intends,' 'estimates,' 'could,' 'should,' 'would,' 'continue,' 'seeks,' or 'anticipates,' and similar words (including their use in the negative) or by discussions of future matters such as the cost of development and potential commercialization of our lead drug candidate and of other new products, expected releases of interim or final data from our clinical trials, possible collaborations, the timing, scope and objectives of our ongoing and planned clinical trials and other statements that are not historical. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of TYME's control. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, that the information is of a preliminary nature and may be subject to change; uncertainties inherent in the cost and outcomes of research and development, including the cost and availability of acceptable-quality clinical supply and the ability to achieve clinical study start and completion dates; the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with early, initial data, including the risk that the final Phase II data may differ from prior study data or preliminary Phase II data; final results of additional clinical trials that may be different from the preliminary data analysis and may not support further clinical development; that past reported data are not necessarily predictive of future patient or clinical data outcomes; whether and when any applications or other submissions for SM-88 may be filed with regulatory authorities; whether and when regulatory authorities may approve any applications or submissions; decisions by regulatory authorities regarding labeling and other matters that could affect commercial availability of SM-88; competitive developments; and the factors described in the section captioned 'Risk Factors' of TYME's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on June 12, 2019, as well as subsequent reports we file from time to time with the U.S. Securities and Exchange Commission (available at www.sec.gov).
The information contained in this press release is as of its release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.
1Manax et al 2019 J Clin Oncol 37, 2019 (suppl 4; abstr 226)
2Statistics adapted from the American Cancer Society's (ACS) publication, Cancer Facts & Figures 2018.
For Investor Relations & Media Inquiries:
Contact:
1-212- 461-2315
investorrelations@tymeinc.com
media@tymeinc.com